作者
Paul Loubet, Charles Burdet, William Vindrios, Nathalie Grall, Michel Wolff, Yazdan Yazdanpanah, Antoine Andremont, Xavier Duval, F-X Lescure
发表日期
2018/2/1
来源
Clinical microbiology and infection
卷号
24
期号
2
页码范围
125-132
出版商
Elsevier
简介
Background
Anti-staphylococcal penicillins (ASPs) are recommended as first-line agents in methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. Concerns about their safety profile have contributed to the increased use of cefazolin. The comparative clinical effectiveness and safety profile of cefazolin versus ASPs for such infections remain unclear. Furthermore, uncertainty persists concerning the use of cefazolin due to controversies over its efficacy in deep MSSA infections and its possible negative ecological impact.
Aims
The aim of this narrative review was to gather and balance available data on the efficacy and safety of cefazolin versus ASPs in the treatment of MSSA bacteraemia and to discuss the potential negative ecological impact of cefazolin.
Sources
PubMed and EMBASE electronic databases were searched up to May 2017 to retrieve available studies on the topic.
Contents
Although …
学术搜索中的文章
P Loubet, C Burdet, W Vindrios, N Grall, M Wolff… - Clinical microbiology and infection, 2018